Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ Form 6-K ________________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Filed in the month of May 2023 for the period ended March 31, 2023 Commission File Number 001-37626 ________________________________________ Mesoblast Limited (Exact name of Registrant as specified in its charter) ________ ...

Mesoblast Limited. (NASDAQ:MESO) Q2 2023 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Silviu Itescu ??? Chief Executive Officer Andrew Chaponnel ??? Chief Financial Officer Conference Call Participants Edward Tenthoff ??? Piper Sandler Swayampakula Ramakanth ??? HCW Silviu Itescu [Call Starts Abruptly] Thank you very much, operator. Good afternoon, good morning to everybody. Thank you for joining us on the operational highlights and financial results for the second quarter fisc ...

Cash Reserves SR-aGVHD is associated with mortality rates as high as 90% mesoblast ASX: MSB; Nasdaq: MESO February 2023 This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ Silviu Itescu Chief Executive Officer and Executive Director Level 38 55 Collins Street Melbourne 3000 Australia (Address of principal executive offices) ________________________________________ Form 6-K ________________________________________ Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Filed in the month of Febru ...

Mesoblast Limited (NASDAQ:MESO) Q1 2023 Results Conference Call November 22, 2022 4:30 PM ET Company Participants Dr. Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Dr. Eric Rose - Chief Medical Officer Conference Call Participants Carvey Leung - Cantor Fitzgerald Edward Tenthoff - Piper Sandler Dr. Silviu Itescu Good morning, good afternoon to the operational highlights and financial results for the quarter ended September 30, 2022, as well as our upcoming Annual General Meeting. Apologies for t ...

Exhibit 99.1 MESOBLAST REPORTS FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR FISCAL YEAR ENDED JUNE 30, 2022 Melbourne, Australia; August 31 and New York, USA; August 30, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended June 30, 2022 and provided an update on upcoming milestones. "I am pleased to report that calendar year 2022 is shaping up to be a tran ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F | REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 | ☐ | | --- | --- | | OR | | | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ☒ | | For the fiscal year ended June 30, 2022 | | | OR | | | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ☐ | | OR | | | SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 1 ...

Mesoblast Limited (NASDAQ:MESO) Q4 2022 Earnings Conference Call August 30, 2022 6:30 PM ET Company Participants Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Eric Rose - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group Edward Tenthoff - Piper Sandler Operator Thank you for standing by. And welcome to the Mesoblast Limited 2022 Full Year Financial Results Conference Call. All participants are in a listen-only mode. A presentation followed by a question-and-answ ...

mesoblast Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases Operational Highlights & Financial Results for the Year Ended June 30, 2022 August 2022 ASX: MSB; Nasdaq: MESO CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achieve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 Filed in the month of June 2022 for the period ended March 31, 2022 Commission File Number 001-37626 Mesoblast Limited (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant's name into English) Australia (Jurisdiction of incorporation or organization) Silviu Itescu Chief Executi ...